论文部分内容阅读
目的研讨肝硬化疾病患者接受生化检查项目诊断的临床价值。方法从我院2014年8月-2016年8月选取50例肝硬化疾病患者参与研究试验,设为Ⅰ组,对该组实施生化项目检测,包括血清TBL、CHE、ALB及AST等指标,并与同期搜集的50例健康体检者(Ⅱ组)的生化检查资料进行对照与分析。结果Ⅰ组接受检测后,显示CHE、ALB两项指标值相比Ⅱ组均显著下降,数据满足(P<0.05),统计学成立。而AST、TBL与TP等几项指标值相比,Ⅰ组相比Ⅱ组均显著升高,数据满足(P<0.05),统计学成立。结论肝硬化疾病患者多项生化项目指标异于健康人群,重视对患者行生化检查,对于早确诊、早治疗均具有积极意义,值得推荐。
Objective To investigate the clinical value of biochemical tests in patients with cirrhosis. Methods Fifty patients with cirrhosis were selected from our hospital from August 2014 to August 2016 to participate in the study. Patients in group Ⅰ were enrolled in this study. Biochemical tests were performed in this group, including serum TBL, CHE, ALB, AST, etc. With the same period collected 50 cases of healthy subjects (group Ⅱ) biochemical test data were compared and analyzed. Results The results of group Ⅰ showed that CHE and ALB decreased significantly compared with group Ⅱ, and the data met (P <0.05), and the statistics was established. The AST, TBL and TP and other indicators of several indicators compared to group Ⅰ compared to the group Ⅱ were significantly increased, the data meet (P <0.05), the statistics established. Conclusions The indexes of many biochemical items in patients with cirrhosis are different from those in healthy people. The emphasis on biochemical examination of patients is of great significance to early diagnosis and early treatment. It is worth recommending.